Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96D31
UPID:
CRCM1_HUMAN
Alternative names:
Protein orai-1; Transmembrane protein 142A
Alternative UPACC:
Q96D31; Q3MHV3; Q6DHX2; Q96BP7; Q96K71
Background:
Calcium release-activated calcium channel protein 1, also known as Protein orai-1 and Transmembrane protein 142A, plays a crucial role in mediating Ca(2+) influx following the depletion of intracellular Ca(2+) stores. This process is activated by the Ca(2+) sensor, STIM1, and is essential for various cellular functions, including the immune response and milk secretion in mammary epithelial cells.
Therapeutic significance:
The protein's involvement in Immunodeficiency 9 and Myopathy, tubular aggregate, 2, underscores its potential as a target for therapeutic intervention. These diseases, resulting from gene variants affecting the protein, highlight its critical role in immune function and muscle pathology. Exploring therapeutic strategies targeting this protein could lead to significant advancements in treating these conditions.